lunes, 26 de enero de 2015

Value of Genetic Testing for Hereditary Colorectal Cancer in a Prob... - PubMed - NCBI

Value of Genetic Testing for Hereditary Colorectal Cancer in a Prob... - PubMed - NCBI

 2015 Jan 14. pii: 0272989X14565820. [Epub ahead of print]

Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample.



. While choices about genetic testing are increasingly common for patients and families, and public opinion surveys suggest public interest in genomics, it is not known how adults from the general population value genetic testing for heritable conditions. We sought to understand in a US sample the relative value of the characteristics of genetic tests to identify risk of hereditary colorectal cancer, among the first genomic applications with evidence to support its translation to clinical settings.


. A Web-enabled choice-format conjoint survey was conducted with adults age 50 years and older from a probability-based US panel. Participants were asked to make a series of choices between 2 hypothetical blood tests that differed in risk of false-negative test, privacy, and cost. Random parameters logit models were used to estimate preferences, the dollar value of genetic information, and intent to have genetic testing.


. A total of 355 individuals completed choice-format questions. Cost and privacy were more highly valued than reducing the chance of a false-negative result. Most (97% [95% confidence interval (CI)], 95%-99%) would have genetic testing to reduce the risk of dying of colorectal cancer in the best scenario (no false negatives, results disclosed to primary care physician). Only 41% (95% CI, 25%-57%) would have genetic testing in the worst case (20% false negatives, results disclosed to insurance company).


. Given the characteristics and levels included in the choice, if false-negative test results are unlikely and results are shared with a primary care physician, the majority would have genetic testing. As genomic services become widely available, primary care professionals will need to be increasingly knowledgeable about genetic testing decisions.
© The Author(s) 2015.


discrete choice; genetics; internal medicine; oncology; utility assessment

[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario